(668 days)
The SENSIMED Triggerfish® is a prescription device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours to identify the window of time to measure intraocular pressure by conventional clinical methods. The SENSIMED Triggerfish® is indicated for patients 22 years of age and older.
SENSIMED Triggerfish® diurnal recording system (hereinafter "STF") is a small patient-worn electronic device intended for use in the home and clinic settings for recording diurnal patterns of IOP fluctuations. The components of the STF are as follows: a hydrophilic, single-use soft contact lens with a strain gauge sensor, antenna with a telemetry chip embedded within it, allowing for continuous wireless recording of changes in ocular dimension, an external adhesive antenna worn around the eye is used to send power to, and receive measurement data from, the embedded system, a pocket-sized, battery-operated recorder worn by the patient during the 24-hour recording session, which is connected to the external adhesive antenna by a data cable. Additional components: charger to recharge the Recorder, Bluetooth universal serial bus (USB) adapter for communication between Recorder and doctor's personal computer (PC), and software for initiation recording sessions, and retrieval & display of the recorded data. The operating principle of the STF is based on the measurement of circumferential changes of the eye ball at the corneoscleral interface by an active strain gauge embedded into the periphery of a soft silicone contact lens ("ocular telemetry sensor"). During the 24-hour recording session, the sensor wirelessly transfers the data to the recording system. At the end of the recording session, all data can be transferred to the PC for review and analysis by a healthcare professional.
The SENSIMED Triggerfish® is a prescription device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours to identify the window of time to measure intraocular pressure by conventional clinical methods. It is indicated for patients 22 years of age and older.
Here's an analysis of the acceptance criteria and the studies that prove the device meets these criteria:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria (from "Special Controls") | Reported Device Performance |
|---|---|
| 1. Clinical performance data must demonstrate that the device and all of its components perform as intended under anticipated conditions of use. The following performance characteristics must be demonstrated: | |
| a. ability of the device to detect diurnal changes | Study TF-1005: Demonstrated repeatability of the mean 24-hour STF profiles in 31 glaucoma and glaucoma suspect subjects, with a strong intraclass correlation (ICC) (0.99) between the mean profiles from two different sessions one week apart. This indicates consistent detection of diurnal patterns. |
| Study TF-1009: Showed that a positive slope was detected on STF profiles in the transition period from wake to sleep (W/S slope) in the study population. Although the results are inconclusive for quantitative characterization of W/S slopes, they show the ability of the device to qualitatively capture "larger and slower patterns" (diurnal changes). A strong correlation (r=0.956, p |
§ 886.1925 Diurnal pattern recorder system.
(a)
Identification. A diurnal pattern recorder system is a nonimplantable, prescription device incorporating a telemetric sensor to detect changes in ocular dimension for monitoring diurnal patterns of intraocular pressure (IOP) fluctuations.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Clinical performance data must demonstrate that the device and all of its components perform as intended under anticipated conditions of use. The following performance characteristics must be demonstrated:
(i) Ability of the device to detect diurnal changes.
(ii) Tolerability of the system at the corneoscleral interface in the intended use population.
(2) Nonclinical testing must validate measurements in an appropriate nonclinical testing model to ensure ability to detect changes in intraocular pressure.
(3) Patient-contacting components must be demonstrated to be biocompatible.
(4) Any component that is intended to contact the eye must be demonstrated to be sterile throughout its intended shelf life.
(5) Software verification, validation, and hazard analysis must be performed.
(6) Performance testing must demonstrate the electromagnetic compatibility and electromagnetic interference of the device.
(7) Performance testing must demonstrate electrical safety of the device.
(8) Labeling must include the following:
(i) Warning against activities and environments that may put the user at greater risk.
(ii) Specific instructions for the safe use of the device, which includes:
(A) Description of all device components and instructions for assembling the device;
(B) Explanations of all available programs and instructions for their use;
(C) Instructions and explanation of all user-interface components;
(D) Instructions on all safety features of the device; and
(E) Instructions for properly maintaining the device.
(iii) A summary of nonclinical testing information to describe EMC safety considerations.
(iv) A summary of safety information obtained from clinical testing.
(v) Patient labeling to convey information regarding appropriate use of device.